Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis

In multiple sclerosis relapses refractory to intravenous corticosteroid therapy, plasma exchange is recommended. Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. We prospectively treated 11 patients with mul...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroinflammation 2012-04, Vol.9 (1), p.80-80, Article 80
Main Authors: Koziolek, Michael J, Tampe, Desiree, Bähr, Matthias, Dihazi, Hassan, Jung, Klaus, Fitzner, Dirk, Klingel, Reinhard, Müller, Gerhard A, Kitze, Bernd
Format: Article
Language:English
Subjects:
Acquisitions & mergers
Adrenal Cortex Hormones - administration & dosage
Adrenal Cortex Hormones - therapeutic use
Adult
Apheresis
Autoimmune diseases
Care and treatment
Corticosteroids
Cytokines
Evoked Potentials, Visual - drug effects
Evoked Potentials, Visual - immunology
Evoked potentials/visual
Female
Follow-Up Studies
Health aspects
Humans
Immunoadsorption
Immunoglobulins
Immunosorbent Techniques - trends
Inflammation
Interleukins
Male
Medical statistics
Middle Aged
Molecular weight
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - epidemiology
Multiple Sclerosis - immunology
Myelin proteins
Nerves
Optic neuritis
Optic Neuritis - drug therapy
Optic Neuritis - epidemiology
Optic Neuritis - immunology
Physiological aspects
Plasma
Platelet Transfusion
Polyvinyl alcohol
Prospective Studies
Protein binding
Proteins
Proteomics
Rheumatology
Tryptophan
Tryptophan - administration & dosage
Tryptophan - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503
cites cdi_FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503
container_end_page 80
container_issue 1
container_start_page 80
container_title Journal of neuroinflammation
container_volume 9
creator Koziolek, Michael J
Tampe, Desiree
Bähr, Matthias
Dihazi, Hassan
Jung, Klaus
Fitzner, Dirk
Klingel, Reinhard
Müller, Gerhard A
Kitze, Bernd
description In multiple sclerosis relapses refractory to intravenous corticosteroid therapy, plasma exchange is recommended. Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. We prospectively treated 11 patients with multiple sclerosis who had optical neuritis and fulfilled the indications for apheresis therapy (Trial registration DE/CA25/00007080-00). In total, five IA treatments were performed using tryptophan-IA. Clinical activity (visual acuity, Expanded Disability Status Scale, Incapacity Status Scale), laboratory values and visual evoked potentials were measured before, during and after IA, with a follow-up of six months. Moreover, proteomic analyses were performed to analyze column-bound proteins as well as corresponding changes in patients' sera. After the third IA, we detected an improvement of vision in eight of eleven patients, whom we termed responders. Amongst these, the mean visual acuity improved from 0.15 ± 0.12 at baseline to 0.47 ± 0.32 after the third IA (P = 0.0252) up to 0.89 ± 0.15 (P 
doi_str_mv 10.1186/1742-2094-9-80
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_63d81d10130547a9a3e386372c0de77f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534283962</galeid><doaj_id>oai_doaj_org_article_63d81d10130547a9a3e386372c0de77f</doaj_id><sourcerecordid>A534283962</sourcerecordid><originalsourceid>FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503</originalsourceid><addsrcrecordid>eNp1ksuP0zAQhyMEYpeFK0cUiXMWv-LHBala8ai0Ehc4W449aV0lcbAdUP97XFrKVizyYezfjD_Nq6peY3SLseTvsGCkIUixRjUSPamuz8LTB_er6kVKO4QoaTl5Xl0R0lLBJL6uYD2OyxSMSyHO2YepzluIZt7Xfqpnkz1MOdU_fd7W4zJkPw9QJztADMmf9JTLy7smQh-NzSHu61BQ1gz1BEv02aeX1bPeDAlenexN9e3jh693n5v7L5_Wd6v7puNI5UZwjAi3Qkro2h5JJcAiTilY0xYLbScVM5ygnoFjmPXWmd50XBDAnLSI3lTrI9cFs9Nz9KOJex2M17-FEDfaxJLaAJpTJ7HDCFPUMmGUoUAlp4JY5ECIvrDeH1nz0o3gbGlENMMF9NIz-a3ehB-aMiyxlAWwOgI6H_4DuPTYMOrDyPRhZFppeSjo7SmJGL4vkLLehSVOpYcaI0qx4ELJv1EbUyrzUx8Kz44-Wb1qKSOSKk5K1O0jUeU4GL0NE_S-6I99sGXaqYz3nDtG-rB9_2b75mHLzuF_1o3-Akld1mI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033176798</pqid></control><display><type>article</type><title>Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis</title><source>PubMed Central</source><source>ProQuest Publicly Available Content database</source><creator>Koziolek, Michael J ; Tampe, Desiree ; Bähr, Matthias ; Dihazi, Hassan ; Jung, Klaus ; Fitzner, Dirk ; Klingel, Reinhard ; Müller, Gerhard A ; Kitze, Bernd</creator><creatorcontrib>Koziolek, Michael J ; Tampe, Desiree ; Bähr, Matthias ; Dihazi, Hassan ; Jung, Klaus ; Fitzner, Dirk ; Klingel, Reinhard ; Müller, Gerhard A ; Kitze, Bernd</creatorcontrib><description>In multiple sclerosis relapses refractory to intravenous corticosteroid therapy, plasma exchange is recommended. Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. We prospectively treated 11 patients with multiple sclerosis who had optical neuritis and fulfilled the indications for apheresis therapy (Trial registration DE/CA25/00007080-00). In total, five IA treatments were performed using tryptophan-IA. Clinical activity (visual acuity, Expanded Disability Status Scale, Incapacity Status Scale), laboratory values and visual evoked potentials were measured before, during and after IA, with a follow-up of six months. Moreover, proteomic analyses were performed to analyze column-bound proteins as well as corresponding changes in patients' sera. After the third IA, we detected an improvement of vision in eight of eleven patients, whom we termed responders. Amongst these, the mean visual acuity improved from 0.15 ± 0.12 at baseline to 0.47 ± 0.32 after the third IA (P = 0.0252) up to 0.89 ± 0.15 (P &lt; 0.0001) at day 180 ± 10 after IA. Soluble interleukin-2 receptor decreased in responders (P = 0.03), whereas in non-responders it did not. Proteomic analyses of proteins adsorbed to IA columns revealed that several significant immunological proteins as well as central nervous system protein fragments, including myelin basic protein, had been removed by IA. IA was effective in the treatment of corticosteroid-refractory optic neuritis. IA influenced the humoral immune response. Strikingly, however, we found strong evidence that demyelination products and immunological mediators were also cleared from plasma by IA.</description><identifier>ISSN: 1742-2094</identifier><identifier>EISSN: 1742-2094</identifier><identifier>DOI: 10.1186/1742-2094-9-80</identifier><identifier>PMID: 22537481</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acquisitions &amp; mergers ; Adrenal Cortex Hormones - administration &amp; dosage ; Adrenal Cortex Hormones - therapeutic use ; Adult ; Apheresis ; Autoimmune diseases ; Care and treatment ; Corticosteroids ; Cytokines ; Evoked Potentials, Visual - drug effects ; Evoked Potentials, Visual - immunology ; Evoked potentials/visual ; Female ; Follow-Up Studies ; Health aspects ; Humans ; Immunoadsorption ; Immunoglobulins ; Immunosorbent Techniques - trends ; Inflammation ; Interleukins ; Male ; Medical statistics ; Middle Aged ; Molecular weight ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - immunology ; Myelin proteins ; Nerves ; Optic neuritis ; Optic Neuritis - drug therapy ; Optic Neuritis - epidemiology ; Optic Neuritis - immunology ; Physiological aspects ; Plasma ; Platelet Transfusion ; Polyvinyl alcohol ; Prospective Studies ; Protein binding ; Proteins ; Proteomics ; Rheumatology ; Tryptophan ; Tryptophan - administration &amp; dosage ; Tryptophan - therapeutic use ; Young Adult</subject><ispartof>Journal of neuroinflammation, 2012-04, Vol.9 (1), p.80-80, Article 80</ispartof><rights>COPYRIGHT 2012 BioMed Central Ltd.</rights><rights>2012 Koziolek et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright ©2012 Koziolek et al.; licensee BioMed Central Ltd. 2012 Koziolek et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503</citedby><cites>FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418188/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1033176798?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22537481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koziolek, Michael J</creatorcontrib><creatorcontrib>Tampe, Desiree</creatorcontrib><creatorcontrib>Bähr, Matthias</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Jung, Klaus</creatorcontrib><creatorcontrib>Fitzner, Dirk</creatorcontrib><creatorcontrib>Klingel, Reinhard</creatorcontrib><creatorcontrib>Müller, Gerhard A</creatorcontrib><creatorcontrib>Kitze, Bernd</creatorcontrib><title>Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis</title><title>Journal of neuroinflammation</title><addtitle>J Neuroinflammation</addtitle><description>In multiple sclerosis relapses refractory to intravenous corticosteroid therapy, plasma exchange is recommended. Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. We prospectively treated 11 patients with multiple sclerosis who had optical neuritis and fulfilled the indications for apheresis therapy (Trial registration DE/CA25/00007080-00). In total, five IA treatments were performed using tryptophan-IA. Clinical activity (visual acuity, Expanded Disability Status Scale, Incapacity Status Scale), laboratory values and visual evoked potentials were measured before, during and after IA, with a follow-up of six months. Moreover, proteomic analyses were performed to analyze column-bound proteins as well as corresponding changes in patients' sera. After the third IA, we detected an improvement of vision in eight of eleven patients, whom we termed responders. Amongst these, the mean visual acuity improved from 0.15 ± 0.12 at baseline to 0.47 ± 0.32 after the third IA (P = 0.0252) up to 0.89 ± 0.15 (P &lt; 0.0001) at day 180 ± 10 after IA. Soluble interleukin-2 receptor decreased in responders (P = 0.03), whereas in non-responders it did not. Proteomic analyses of proteins adsorbed to IA columns revealed that several significant immunological proteins as well as central nervous system protein fragments, including myelin basic protein, had been removed by IA. IA was effective in the treatment of corticosteroid-refractory optic neuritis. IA influenced the humoral immune response. Strikingly, however, we found strong evidence that demyelination products and immunological mediators were also cleared from plasma by IA.</description><subject>Acquisitions &amp; mergers</subject><subject>Adrenal Cortex Hormones - administration &amp; dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Apheresis</subject><subject>Autoimmune diseases</subject><subject>Care and treatment</subject><subject>Corticosteroids</subject><subject>Cytokines</subject><subject>Evoked Potentials, Visual - drug effects</subject><subject>Evoked Potentials, Visual - immunology</subject><subject>Evoked potentials/visual</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunoadsorption</subject><subject>Immunoglobulins</subject><subject>Immunosorbent Techniques - trends</subject><subject>Inflammation</subject><subject>Interleukins</subject><subject>Male</subject><subject>Medical statistics</subject><subject>Middle Aged</subject><subject>Molecular weight</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - immunology</subject><subject>Myelin proteins</subject><subject>Nerves</subject><subject>Optic neuritis</subject><subject>Optic Neuritis - drug therapy</subject><subject>Optic Neuritis - epidemiology</subject><subject>Optic Neuritis - immunology</subject><subject>Physiological aspects</subject><subject>Plasma</subject><subject>Platelet Transfusion</subject><subject>Polyvinyl alcohol</subject><subject>Prospective Studies</subject><subject>Protein binding</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Rheumatology</subject><subject>Tryptophan</subject><subject>Tryptophan - administration &amp; dosage</subject><subject>Tryptophan - therapeutic use</subject><subject>Young Adult</subject><issn>1742-2094</issn><issn>1742-2094</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ksuP0zAQhyMEYpeFK0cUiXMWv-LHBala8ai0Ehc4W449aV0lcbAdUP97XFrKVizyYezfjD_Nq6peY3SLseTvsGCkIUixRjUSPamuz8LTB_er6kVKO4QoaTl5Xl0R0lLBJL6uYD2OyxSMSyHO2YepzluIZt7Xfqpnkz1MOdU_fd7W4zJkPw9QJztADMmf9JTLy7smQh-NzSHu61BQ1gz1BEv02aeX1bPeDAlenexN9e3jh693n5v7L5_Wd6v7puNI5UZwjAi3Qkro2h5JJcAiTilY0xYLbScVM5ygnoFjmPXWmd50XBDAnLSI3lTrI9cFs9Nz9KOJex2M17-FEDfaxJLaAJpTJ7HDCFPUMmGUoUAlp4JY5ECIvrDeH1nz0o3gbGlENMMF9NIz-a3ehB-aMiyxlAWwOgI6H_4DuPTYMOrDyPRhZFppeSjo7SmJGL4vkLLehSVOpYcaI0qx4ELJv1EbUyrzUx8Kz44-Wb1qKSOSKk5K1O0jUeU4GL0NE_S-6I99sGXaqYz3nDtG-rB9_2b75mHLzuF_1o3-Akld1mI</recordid><startdate>20120426</startdate><enddate>20120426</enddate><creator>Koziolek, Michael J</creator><creator>Tampe, Desiree</creator><creator>Bähr, Matthias</creator><creator>Dihazi, Hassan</creator><creator>Jung, Klaus</creator><creator>Fitzner, Dirk</creator><creator>Klingel, Reinhard</creator><creator>Müller, Gerhard A</creator><creator>Kitze, Bernd</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120426</creationdate><title>Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis</title><author>Koziolek, Michael J ; Tampe, Desiree ; Bähr, Matthias ; Dihazi, Hassan ; Jung, Klaus ; Fitzner, Dirk ; Klingel, Reinhard ; Müller, Gerhard A ; Kitze, Bernd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acquisitions &amp; mergers</topic><topic>Adrenal Cortex Hormones - administration &amp; dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Apheresis</topic><topic>Autoimmune diseases</topic><topic>Care and treatment</topic><topic>Corticosteroids</topic><topic>Cytokines</topic><topic>Evoked Potentials, Visual - drug effects</topic><topic>Evoked Potentials, Visual - immunology</topic><topic>Evoked potentials/visual</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunoadsorption</topic><topic>Immunoglobulins</topic><topic>Immunosorbent Techniques - trends</topic><topic>Inflammation</topic><topic>Interleukins</topic><topic>Male</topic><topic>Medical statistics</topic><topic>Middle Aged</topic><topic>Molecular weight</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - immunology</topic><topic>Myelin proteins</topic><topic>Nerves</topic><topic>Optic neuritis</topic><topic>Optic Neuritis - drug therapy</topic><topic>Optic Neuritis - epidemiology</topic><topic>Optic Neuritis - immunology</topic><topic>Physiological aspects</topic><topic>Plasma</topic><topic>Platelet Transfusion</topic><topic>Polyvinyl alcohol</topic><topic>Prospective Studies</topic><topic>Protein binding</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Rheumatology</topic><topic>Tryptophan</topic><topic>Tryptophan - administration &amp; dosage</topic><topic>Tryptophan - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koziolek, Michael J</creatorcontrib><creatorcontrib>Tampe, Desiree</creatorcontrib><creatorcontrib>Bähr, Matthias</creatorcontrib><creatorcontrib>Dihazi, Hassan</creatorcontrib><creatorcontrib>Jung, Klaus</creatorcontrib><creatorcontrib>Fitzner, Dirk</creatorcontrib><creatorcontrib>Klingel, Reinhard</creatorcontrib><creatorcontrib>Müller, Gerhard A</creatorcontrib><creatorcontrib>Kitze, Bernd</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of neuroinflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koziolek, Michael J</au><au>Tampe, Desiree</au><au>Bähr, Matthias</au><au>Dihazi, Hassan</au><au>Jung, Klaus</au><au>Fitzner, Dirk</au><au>Klingel, Reinhard</au><au>Müller, Gerhard A</au><au>Kitze, Bernd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis</atitle><jtitle>Journal of neuroinflammation</jtitle><addtitle>J Neuroinflammation</addtitle><date>2012-04-26</date><risdate>2012</risdate><volume>9</volume><issue>1</issue><spage>80</spage><epage>80</epage><pages>80-80</pages><artnum>80</artnum><issn>1742-2094</issn><eissn>1742-2094</eissn><abstract>In multiple sclerosis relapses refractory to intravenous corticosteroid therapy, plasma exchange is recommended. Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. We prospectively treated 11 patients with multiple sclerosis who had optical neuritis and fulfilled the indications for apheresis therapy (Trial registration DE/CA25/00007080-00). In total, five IA treatments were performed using tryptophan-IA. Clinical activity (visual acuity, Expanded Disability Status Scale, Incapacity Status Scale), laboratory values and visual evoked potentials were measured before, during and after IA, with a follow-up of six months. Moreover, proteomic analyses were performed to analyze column-bound proteins as well as corresponding changes in patients' sera. After the third IA, we detected an improvement of vision in eight of eleven patients, whom we termed responders. Amongst these, the mean visual acuity improved from 0.15 ± 0.12 at baseline to 0.47 ± 0.32 after the third IA (P = 0.0252) up to 0.89 ± 0.15 (P &lt; 0.0001) at day 180 ± 10 after IA. Soluble interleukin-2 receptor decreased in responders (P = 0.03), whereas in non-responders it did not. Proteomic analyses of proteins adsorbed to IA columns revealed that several significant immunological proteins as well as central nervous system protein fragments, including myelin basic protein, had been removed by IA. IA was effective in the treatment of corticosteroid-refractory optic neuritis. IA influenced the humoral immune response. Strikingly, however, we found strong evidence that demyelination products and immunological mediators were also cleared from plasma by IA.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>22537481</pmid><doi>10.1186/1742-2094-9-80</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-2094
ispartof Journal of neuroinflammation, 2012-04, Vol.9 (1), p.80-80, Article 80
issn 1742-2094
1742-2094
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_63d81d10130547a9a3e386372c0de77f
source PubMed Central; ProQuest Publicly Available Content database
subjects Acquisitions & mergers
Adrenal Cortex Hormones - administration & dosage
Adrenal Cortex Hormones - therapeutic use
Adult
Apheresis
Autoimmune diseases
Care and treatment
Corticosteroids
Cytokines
Evoked Potentials, Visual - drug effects
Evoked Potentials, Visual - immunology
Evoked potentials/visual
Female
Follow-Up Studies
Health aspects
Humans
Immunoadsorption
Immunoglobulins
Immunosorbent Techniques - trends
Inflammation
Interleukins
Male
Medical statistics
Middle Aged
Molecular weight
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - epidemiology
Multiple Sclerosis - immunology
Myelin proteins
Nerves
Optic neuritis
Optic Neuritis - drug therapy
Optic Neuritis - epidemiology
Optic Neuritis - immunology
Physiological aspects
Plasma
Platelet Transfusion
Polyvinyl alcohol
Prospective Studies
Protein binding
Proteins
Proteomics
Rheumatology
Tryptophan
Tryptophan - administration & dosage
Tryptophan - therapeutic use
Young Adult
title Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A36%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoadsorption%20therapy%20in%20patients%20with%20multiple%20sclerosis%20with%20steroid-refractory%20optical%20neuritis&rft.jtitle=Journal%20of%20neuroinflammation&rft.au=Koziolek,%20Michael%20J&rft.date=2012-04-26&rft.volume=9&rft.issue=1&rft.spage=80&rft.epage=80&rft.pages=80-80&rft.artnum=80&rft.issn=1742-2094&rft.eissn=1742-2094&rft_id=info:doi/10.1186/1742-2094-9-80&rft_dat=%3Cgale_doaj_%3EA534283962%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b609t-761026c788eb5f0897ec0633eca5063e5b894a620f4ed414fcdafab672e162503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1033176798&rft_id=info:pmid/22537481&rft_galeid=A534283962&rfr_iscdi=true